Company registration number 01843037 (England and Wales)
WESTLAND NURSERIES (OFFENHAM) LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
WESTLAND NURSERIES (OFFENHAM) LIMITED
COMPANY INFORMATION
Directors
Mr M Boers
Mrs J Boers
Mr W Boers
Secretary
Mrs J Boers
Company number
01843037
Registered office
Station Road
Offenham
Evesham
Worcestershire
United Kingdom
WR11 8LW
Auditor
Azets Audit Services
Epsilon House
The Square
Gloucester Business Park
Gloucester
United Kingdom
GL3 4AD
WESTLAND NURSERIES (OFFENHAM) LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Independent auditor's report
4 - 6
Statement of income and retained earnings
7
Statement of financial position
8
Statement of cash flows
9
Notes to the financial statements
10 - 25
WESTLAND NURSERIES (OFFENHAM) LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -
The directors present the strategic report for the year ended 31 December 2024.
Results for the year
For the 2024 financial year, the business recorded a 3.4% increase in revenue from its core produce sales compared to 2023, with overall revenue for 2024 being 2.4% higher on 2023.
Erratic energy prices over recent years have meant a focus onto site rationalisation and ensuring production is as energy efficient as possible. The streamlining of major input costs has come to the fore to reduce exposure in future years, although a rise in energy costs over 2024 largely contributed to a slight reduction in profitability compared to 2023, but remaining at consistent levels to previous years. Continued development and investment into facilities, production processes and efficiency gains is anticipated to further support growth in productivity and profitability.
Operationally, the company continues to closely monitor turnover levels, gross profit and administration costs in order to maintain and improve performance.
Key performance indicators
Key performance indicators (KPIs) over 2024 were as follows:
Revenue increase 2024 to 2023 2.36%
Gross profit percentage for 2024 24.42%
Net profit percentage for 2024 7.47%
Building on the revenue growth and profitability for 2024, improvement in the KPIs is targeted for 2025.
Principal risks and uncertainties
The principal risk to the business would arise from food scares associated to salads, salad products including sprouted seeds, even when involving product not directly associated with the business.
Continual development of growing systems, ancillary equipment and support services assist the company in managing this potential risk.
The business operates a full and robust testing schedule that is regularly audited, to further assist in its risk management in this area.
Exposure to global rises in energy costs has also become more significant to the risk profile of the business in recent years. This risk continues to be managed by regularly reviewing and negotiating terms with suppliers, with further mitigation provided by the on-site energy generation capacity from investments made by the business. Further investment in on-site energy capacity is also planned to manage and mitigate future risk in this area.
Future developments
The performance of key financial indicators over recent years has allowed renewed focus on investments and improvements to production aimed at achieving efficiencies arising from new processes and technology. Alongside continued support from the company’s bankers, at the end of 2024 there was construction work underway on new glasshouse facilities. This investment in production processes through improved facilities, growing systems, lighting and materials will provide a platform for further growth in future revenue and profitability.
Looking ahead to the future development of the business, the directors intend to continue a focus on new product and revenue stream development, alongside further investment in its production facilities and output processes to achieve efficiencies. Continued investment in energy generation is also planned to secure further on-site capacity and mitigate exposure to wholesale energy price volatility.
WESTLAND NURSERIES (OFFENHAM) LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
Mr M Boers
Director
30 September 2025
WESTLAND NURSERIES (OFFENHAM) LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -
The directors present their annual report and financial statements for the year ended 31 December 2024.
Principal activities
The principal activity of the company continued to be that of food production and plant propagation.
Results and dividends
The results for the year are set out on page 7.
The total distribution of dividends for the year ended 31 December 2024 is £681,111 (2023: £277,778).
Directors
The directors who held office during the current and previous period and up to the date of signature of the financial statements were as follows:
Mr M Boers
Mrs J Boers
Mr W Boers
Statement of directors' responsibilities
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Statement of disclosure to auditor
So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.
On behalf of the board
Mr M Boers
Director
30 September 2025
WESTLAND NURSERIES (OFFENHAM) LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF WESTLAND NURSERIES (OFFENHAM) LIMITED
- 4 -
Opinion
We have audited the financial statements of Westland Nurseries (Offenham) Limited (the 'company') for the year ended 31 December 2024 which comprise the statement of income and retained earnings, the statement of financial position, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
WESTLAND NURSERIES (OFFENHAM) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF WESTLAND NURSERIES (OFFENHAM) LIMITED
- 5 -
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
WESTLAND NURSERIES (OFFENHAM) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF WESTLAND NURSERIES (OFFENHAM) LIMITED
- 6 -
Extent to which the audit was considered capable of detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above and on the Financial Reporting Council’s website, to detect material misstatements in respect of irregularities, including fraud.
We obtain and update our understanding of the entity, its activities, its control environment, and likely future developments, including in relation to the legal and regulatory framework applicable and how the entity is complying with that framework. Based on this understanding, we identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. This includes consideration of the risk of acts by the entity that were contrary to applicable laws and regulations, including fraud.
In response to the risk of irregularities and non-compliance with laws and regulations, including fraud, we designed procedures which included:
Enquiry of management and those charged with governance around actual and potential litigation and claims as well as actual, suspected and alleged fraud;
Reviewing minutes of meetings of those charged with governance;
Assessing the extent of compliance with the laws and regulations considered to have a direct material effect on the financial statements or the operations of the company through enquiry and inspection;
Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations;
Performing audit work over the risk of management bias and override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for indicators of potential bias.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Rebecca Hudson
Senior Statutory Auditor
For and on behalf of Azets Audit Services
30 September 2025
Chartered Accountants
Statutory Auditor
Epsilon House
The Square
Gloucester Business Park
Gloucester
United Kingdom
GL3 4AD
WESTLAND NURSERIES (OFFENHAM) LIMITED
STATEMENT OF INCOME AND RETAINED EARNINGS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2024
2023
Notes
£
£
Revenue
16,211,806
15,837,820
Cost of sales
(12,253,355)
(11,693,064)
Gross profit
3,958,451
4,144,756
Administrative expenses
(1,995,863)
(1,800,020)
Other operating income
106,421
12,396
Operating profit
3
2,069,009
2,357,132
Investment income
6
7,702
Finance costs
7
(858,311)
(810,684)
Profit before taxation
1,210,698
1,554,150
Tax on profit
8
(846,014)
(417,111)
Profit for the financial year
364,684
1,137,039
Retained earnings brought forward
7,957,864
7,098,603
Dividends
9
(681,111)
(277,778)
Retained earnings carried forward
7,641,437
7,957,864
The income statement has been prepared on the basis that all operations are continuing operations.
WESTLAND NURSERIES (OFFENHAM) LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 DECEMBER 2024
31 December 2024
- 8 -
2024
2023
Notes
£
£
£
£
Non-current assets
Intangible assets
10
2,054,305
2,162,426
Property, plant and equipment
11
16,791,643
14,088,441
18,845,948
16,250,867
Current assets
Inventories
12
1,092,219
1,150,774
Trade and other receivables
13
4,510,885
4,134,418
Cash and cash equivalents
920
43,086
5,604,024
5,328,278
Current liabilities
14
(3,694,512)
(2,397,948)
Net current assets
1,909,512
2,930,330
Total assets less current liabilities
20,755,460
19,181,197
Non-current liabilities
15
(11,384,409)
(10,339,733)
Provisions for liabilities
Deferred tax liability
18
1,729,414
883,400
(1,729,414)
(883,400)
Net assets
7,641,637
7,958,064
Equity
Called up share capital
20
200
200
Retained earnings
7,641,437
7,957,864
Total equity
7,641,637
7,958,064
The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
Mr M Boers
Director
Company Registration No. 01843037
WESTLAND NURSERIES (OFFENHAM) LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 9 -
2024
2023
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
26
3,491,610
3,640,635
Interest paid
(858,311)
(810,684)
Net cash inflow from operating activities
2,633,299
2,829,951
Investing activities
Purchase of intangible assets
(14,565)
Purchase of property, plant and equipment
(4,209,224)
(2,576,707)
Proceeds from disposal of property, plant and equipment
10,191
3,498
Net cash used in investing activities
(4,199,033)
(2,587,774)
Financing activities
Proceeds from borrowings
435,166
Repayment of borrowings
(91,613)
Proceeds from new bank loans
1,898,619
Repayment of bank loans
(372,844)
(417,216)
(Payment of) / new finance leases obligations
(3,938)
562,624
Dividends paid
(681,111)
(277,778)
Amounts repaid / (withdrawn) by directors
369,621
(122,246)
Net cash generated from financing activities
1,118,734
180,550
Net (decrease)/increase in cash and cash equivalents
(447,000)
422,727
Cash and cash equivalents at beginning of year
43,086
(379,641)
Cash and cash equivalents at end of year
(403,914)
43,086
Relating to:
Cash at bank and in hand
920
43,086
Bank overdrafts included in creditors payable within one year
(404,834)
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
1
Accounting policies
Company information
Westland Nurseries (Offenham) Limited is a private company limited by shares incorporated in England and Wales. The registered office is Station Road, Offenham, Evesham, Worcestershire, United Kingdom, WR11 8LW.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Revenue
Revenue is measured at the fair value of the consideration received or receivable for goods supplied, stated net of discounts, rebates, value added tax and other sales taxes.
Sale of goods
The company sells a wide variety of produce products. Sale of goods are recognised when the company has dispatched the goods to the customer and no other significant obligation remains unfulfilled that may affect the customers acceptance of the products.
Interest receivable
Interest receivable is recognised within the financial statements and attributed to the financial period to which it relates.
1.4
Research and development expenditure
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.
Research and development expenditure is written off as incurred, except that development expenditure incurred on an individual project is capitalised as an intangible asset where the company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the asset and the ability to measure reliably the expenditure during development.
Following initial recognition of the development expenditure as an asset, the cost model is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised evenly over the period of expected future benefit. During the period of development the asset is tested for impairment annually.
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 11 -
1.5
Intangible fixed assets other than goodwill
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Development costs are being amortised on a reducing balance over 20 years.
1.6
Property, plant and equipment
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Land and buildings Freehold
varying rates on cost of buildings
Glasshouses
5% on cost
Plant and machinery
varying rates over the life of the asset
Computer costs
33% on cost
Motor vehicles
25% on reducing balance
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.7
Impairment of non-current assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Where a reasonable and consistent basis of allocation can be identified, assets are allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 12 -
1.8
Inventories
Inventories are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition.
Inventories held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of inventories over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.9
Financial instruments
Other financial assets
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Impairment of financial assets
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Other financial liabilities
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 13 -
Derecognition of financial liabilities
Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.
1.10
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.11
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.12
Provisions
Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 14 -
1.13
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or non-current assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
1.14
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.15
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the statement of financial position as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.
1.16
Government grants
Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.
A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
2
Judgements and key sources of estimation uncertainty
(Continued)
- 15 -
Key sources of estimation uncertainty
The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.
Useful lives of tangible assets
The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful lives and residual values of the assets. The useful lives and residual values are re-assessed at each reporting date. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets.
Rates of depreciation charged are considered on a line by line basis and disclosed within the accounting policy for depreciation.
Refer to tangible fixed assets note for the carrying amount for each class of assets.
3
Operating profit
2024
2023
Operating profit for the year is stated after charging/(crediting):
£
£
Research and development costs
14,019
-
Government grants
(65,268)
(5,439)
Fees payable to the company's auditor for the audit of the company's financial statements
14,850
14,500
Depreciation of owned property, plant and equipment
1,358,581
1,217,016
Depreciation of property, plant and equipment held under finance leases
144,490
141,269
Profit on disposal of property, plant and equipment
(7,240)
(2,514)
Amortisation of intangible assets
108,121
113,698
4
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2024
2023
Number
Number
Productive staff
88
85
Administrative staff
8
11
Directors
3
3
Total
99
99
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
4
Employees
(Continued)
- 16 -
Their aggregate remuneration comprised:
2024
2023
£
£
Wages and salaries
3,161,912
2,770,328
Social security costs
288,623
270,297
Pension costs
57,605
49,750
3,508,140
3,090,375
5
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
192,439
195,603
Company pension contributions to defined contribution schemes
2,642
2,781
195,081
198,384
The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 3 (2023 - 3).
6
Investment income
2024
2023
£
£
Interest income
Other interest income
7,702
7
Finance costs
2024
2023
£
£
Interest on financial liabilities measured at amortised cost:
Interest on bank overdrafts and loans
684,011
695,265
Other interest on financial liabilities
10,673
684,011
705,938
Other finance costs:
Interest on finance leases and hire purchase contracts
174,300
104,746
858,311
810,684
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 17 -
8
Taxation
2024
2023
£
£
Deferred tax
Origination and reversal of timing differences
313,790
417,111
Adjustment in respect of prior periods
532,224
Total deferred tax
846,014
417,111
The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:
2024
2023
£
£
Profit before taxation
1,210,698
1,554,150
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
302,675
365,536
Tax effect of expenses that are not deductible in determining taxable profit
11,116
10,023
Effect of change in corporation tax rate
22,880
Amortisation on assets not qualifying for tax allowances
26,742
Deferred tax adjustments in respect of prior years
532,223
Enhanced capital allowances
(8,070)
Taxation charge for the year
846,014
417,111
9
Dividends
2024
2023
£
£
Interim paid
681,111
277,778
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 18 -
10
Intangible fixed assets
Development costs
£
Cost
At 1 January 2024 and 31 December 2024
3,469,099
Amortisation and impairment
At 1 January 2024
1,306,673
Amortisation charged for the year
108,121
At 31 December 2024
1,414,794
Carrying amount
At 31 December 2024
2,054,305
At 31 December 2023
2,162,426
11
Property, plant and equipment
Land and buildings Freehold
Glasshouses
Plant and machinery
Computer costs
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 January 2024
2,312,313
14,144,936
12,832,657
199,938
413,992
29,903,836
Additions
245,519
3,305,516
596,439
61,750
4,209,224
Disposals
(45,575)
(45,575)
At 31 December 2024
2,557,832
17,450,452
13,429,096
199,938
430,167
34,067,485
Depreciation and impairment
At 1 January 2024
347,192
6,884,804
8,174,935
170,872
237,592
15,815,395
Depreciation charged in the year
34,802
480,634
923,156
15,114
49,365
1,503,071
Eliminated in respect of disposals
(42,624)
(42,624)
At 31 December 2024
381,994
7,365,438
9,098,091
185,986
244,333
17,275,842
Carrying amount
At 31 December 2024
2,175,838
10,085,014
4,331,005
13,952
185,834
16,791,643
At 31 December 2023
1,965,121
7,260,132
4,657,722
29,066
176,400
14,088,441
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
11
Property, plant and equipment
(Continued)
- 19 -
The net carrying value of tangible fixed assets includes the following in respect of assets held under finance leases or hire purchase contracts.
2024
2023
£
£
Plant and machinery
547,164
644,452
Motor vehicles
41,869
55,825
Glasshouses
741,690
774,935
1,330,723
1,475,212
12
Inventories
2024
2023
£
£
Deadstock
513,872
616,323
Growing crops
578,347
534,451
1,092,219
1,150,774
13
Trade and other receivables
2024
2023
Amounts falling due within one year:
£
£
Trade receivables
2,091,307
2,098,158
Other receivables
1,805,953
1,566,191
Prepayments and accrued income
613,625
470,069
4,510,885
4,134,418
14
Current liabilities
2024
2023
Notes
£
£
Bank loans and overdrafts
16
886,135
324,241
Obligations under finance leases
17
445,519
373,775
Other borrowings
16
91,614
50,124
Trade payables
949,447
824,700
Taxation and social security
122,207
108,185
Other payables
296,439
160,901
Accruals and deferred income
903,151
556,022
3,694,512
2,397,948
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 20 -
15
Non-current liabilities
2024
2023
Notes
£
£
Bank loans and overdrafts
16
9,821,588
8,452,873
Obligations under finance leases
17
1,120,497
1,196,179
Other borrowings
16
251,939
385,042
Accruals and deferred income
190,385
305,639
11,384,409
10,339,733
Amounts included above which fall due after five years are as follows:
Payable by instalments
7,815,884
7,155,909
16
Borrowings
2024
2023
£
£
Bank loans
10,302,889
8,777,114
Bank overdrafts
404,834
Other loans
343,553
435,166
11,051,276
9,212,280
Payable within one year
977,749
374,365
Payable after one year
10,073,527
8,837,915
The bank loans are secured by fixed and floating charges over the undertaking and all property and assets present and future, including goodwill, uncalled capital, buildings, fixtures, fixed plant and machinery.
The bank loans are repayable in monthly instalments of capital and interest over a period of 20 years, and accrue interest at rates ranging from 2.05-2.85% over the Bank of England base rate.
Other loans are unsecured, repayable in monthly instalments over 5 years, and accrue interest at 4.25% over the Bank of England base rate.
17
Finance lease obligations
2024
2023
Future minimum lease payments due under finance leases:
£
£
Within one year
445,519
373,775
In two to five years
1,120,497
1,196,179
1,566,016
1,569,954
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
17
Finance lease obligations
(Continued)
- 21 -
The company's finance lease obligations are on monthly repayment terms over periods ranging from 3-7 years. Interest rates on amounts financed range from fixed rates of 7.98-9.45% and variable rate of 3.85% over Bank of England base rate.
The company has given security over financed plant and machinery in respect of its finance lease obligations.
18
Deferred taxation
The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:
Liabilities
Liabilities
2024
2023
Balances:
£
£
Accelerated capital allowances
3,084,254
2,425,288
Tax losses
(1,353,410)
(1,540,886)
Other timing differences
(1,430)
(1,002)
1,729,414
883,400
2024
Movements in the year:
£
Liability at 1 January 2024
883,400
Charge to profit or loss
846,014
Liability at 31 December 2024
1,729,414
The deferred tax liability set out above is expected to reverse in the future and relates to accelerated capital allowances and utilisation of tax losses that are expected to mature within the same period.
19
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
57,605
49,750
The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.
20
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
200
200
200
200
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
20
Share capital
(Continued)
- 22 -
The company has one class of ordinary shares which rank pari passu in all respects relating to participation in dividends, voting rights and capital distributions. The shares do not carry a right to fixed income.
21
Operating lease commitments
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
2024
2023
£
£
Within one year
528
2,768
Between two and five years
528
528
3,296
22
Capital commitments
Amounts contracted for but not provided in the financial statements:
2024
2023
£
£
Acquisition of property, plant and equipment
3,229,199
-
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 23 -
23
Related party transactions
Transactions with related parties
During the year the company entered into the following transactions with related parties:
Services provided
Services received
2024
2023
2024
2023
£
£
£
£
Other related parties
523,847
661,518
456,110
697,391
The following amounts were outstanding at the reporting end date:
2024
2023
Amounts due from related parties
£
£
Other related parties
1,592,423
1,015,175
Other information
During the year, directors close family remuneration totalled £38,781 (2023: £50,827).
Included within other receivables at the reporting date are amounts due from related parties of £30,762 (2023: £29,825). These amounts are unsecured, interest free and repayable on demand.
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 24 -
24
Directors' transactions
Dividends totalling £681,111 (2023 - £277,778) were paid in the year in respect of shares held by the company's directors.
The directors have given a personal guarantee to the company's bank of £1,000,000.
Loans have been granted by the company to its directors as follows. The loans are repayable on demand and attract interest at the HMRC official rate of interest.
Description
Opening balance
Amounts advanced
Interest charged
Amounts repaid
Closing balance
£
£
£
£
£
M Boers & J Boers
2023
233,015
401,720
7,582
(272,696)
369,621
2024
369,621
195,907
-
(613,561)
(48,033)
W Boers
2023
-
21,000
120
(27,778)
(6,658)
2024
(6,658)
23,000
-
(68,111)
(51,769)
WESTLAND NURSERIES (OFFENHAM) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 25 -
25
Ultimate controlling party
During the current and previous year the company was controlled by the director M Boers, who owns 55% of the issued share capital.
26
Cash generated from operations
2024
2023
£
£
Profit for the year after tax
364,684
1,137,039
Adjustments for:
Taxation charged
846,014
417,111
Finance costs
858,311
810,684
Investment income
(7,702)
Gain on disposal of property, plant and equipment
(7,240)
(2,514)
Amortisation and impairment of intangible assets
108,121
113,698
Depreciation and impairment of property, plant and equipment
1,503,071
1,358,285
Movements in working capital:
Decrease in inventories
58,555
15,720
Increase in trade and other receivables
(746,088)
(34,698)
Increase/(decrease) in trade and other payables
506,182
(166,988)
Cash generated from operations
3,491,610
3,640,635
27
Analysis of changes in net debt
1 January 2024
Cash flows
31 December 2024
£
£
£
Cash at bank and in hand
43,086
(42,166)
920
Bank overdrafts
(404,834)
(404,834)
43,086
(447,000)
(403,914)
Borrowings excluding overdrafts
(9,212,280)
(1,434,162)
(10,646,442)
Obligations under finance leases
(1,569,954)
3,938
(1,566,016)
(10,739,148)
(1,877,224)
(12,616,372)
2024-12-312024-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.100Mr M BoersMr W BoersW BoersMrs J Boers018430372024-01-012024-12-3101843037bus:Director12024-01-012024-12-3101843037bus:CompanySecretaryDirector12024-01-012024-12-3101843037bus:Director22024-01-012024-12-3101843037bus:CompanySecretary12024-01-012024-12-3101843037bus:Director32024-01-012024-12-3101843037bus:RegisteredOffice2024-01-012024-12-31018430372024-12-31018430372023-01-012023-12-3101843037core:RetainedEarningsAccumulatedLosses2023-12-3101843037core:RetainedEarningsAccumulatedLosses2022-12-3101843037core:ShareCapital2024-12-3101843037core:ShareCapital2023-12-3101843037core:RetainedEarningsAccumulatedLosses2024-12-3101843037core:RetainedEarningsAccumulatedLosses2023-12-31018430372023-12-3101843037core:ShareCapitalOrdinaryShareClass12024-12-3101843037core:ShareCapitalOrdinaryShareClass12023-12-3101843037core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3101843037core:OtherResidualIntangibleAssets2024-12-3101843037core:OtherResidualIntangibleAssets2023-12-3101843037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-12-3101843037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3101843037core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-3101843037core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3101843037core:PlantMachinery2024-12-3101843037core:ComputerEquipment2024-12-3101843037core:MotorVehicles2024-12-3101843037core:LandBuildingscore:OwnedOrFreeholdAssets2023-12-3101843037core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3101843037core:PlantMachinery2023-12-3101843037core:ComputerEquipment2023-12-3101843037core:MotorVehicles2023-12-3101843037core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3101843037core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3101843037core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3101843037core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3101843037core:CurrentFinancialInstruments2024-12-3101843037core:CurrentFinancialInstruments2023-12-3101843037core:Non-currentFinancialInstruments2024-12-3101843037core:Non-currentFinancialInstruments2023-12-310184303712024-01-012024-12-310184303712023-01-012023-12-310184303722024-01-012024-12-310184303722023-01-012023-12-31018430372023-12-31018430372022-12-3101843037core:WithinOneYear2024-12-3101843037core:WithinOneYear2023-12-3101843037core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3101843037core:LandBuildingscore:OwnedOrFreeholdAssets2024-01-012024-12-3101843037core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-01-012024-12-3101843037core:PlantMachinery2024-01-012024-12-3101843037core:ComputerEquipment2024-01-012024-12-3101843037core:MotorVehicles2024-01-012024-12-3101843037core:UKTax2024-01-012024-12-3101843037core:UKTax2023-01-012023-12-3101843037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-12-3101843037core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-01-012024-12-3101843037core:LandBuildingscore:OwnedOrFreeholdAssets2023-12-3101843037core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3101843037core:PlantMachinery2023-12-3101843037core:ComputerEquipment2023-12-3101843037core:MotorVehicles2023-12-3101843037core:BetweenTwoFiveYears2024-12-3101843037core:BetweenTwoFiveYears2023-12-3101843037bus:OrdinaryShareClass12024-01-012024-12-3101843037bus:OrdinaryShareClass12024-12-3101843037bus:OrdinaryShareClass12023-12-3101843037bus:PrivateLimitedCompanyLtd2024-01-012024-12-3101843037bus:FRS1022024-01-012024-12-3101843037bus:Audited2024-01-012024-12-3101843037bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP